Elevated levels of serum aldolase A in patients with renal cell carcinoma.
To clarify whether serum aldolase A is a useful biomarker for renal cell carcinoma (RCC), we determined serum levels of the aldolase A isozyme by an enzyme immunoassay in patients suffering from RCC, other urological tumors, and benign urological diseases. Forty-six of 126 patients with RCC (37%) had elevated serum aldolase A. The positive rates were 23% in stage I, 40% in stage II, 63% in stage III, and 46% in stage IV. In 10 (83%) of 12 patients whose serum levels had been elevated preoperatively, these were reduced to within the normal range after nephrectomy. Four of 7 patients (57%) with progressive disease had elevated levels of aldolase A. In contrast, the positive rates were only 9.9% in 71 patients with other urological tumors and 5.8% in 52 cases of benign urological diseases. High concentrations of aldolase A isozyme in RCC tissues might be reflected in elevated serum levels. The present findings indicate that serum aldolase A is a useful biomarker for monitoring the clinical course of patients with RCC.
Takashi
M
M
Department of Urology, Nagoya University School of Medicine, Japan.
Zhu
Y
Y
Nakano
Y
Y
Miyake
K
K
Kato
K
K
D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000175:diagnosis*; D004796:Clinical Enzyme Tests; D005260:Female; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques; D007680:Kidney Neoplasms / Q000097:blood / Q000175:diagnosis*; D008297:Male; D014570:Urologic Diseases / Q000097:blood; D014571:Urologic Neoplasms / Q000097:blood
D014408:Biomarkers, Tumor; D005634:Fructose-Bisphosphate Aldolase